Asunto(s)
Hemorragia , Prótesis de Cadera , Cirrosis Hepática Alcohólica , Anciano , Trastornos de la Coagulación Sanguínea/complicaciones , Trastornos de la Coagulación Sanguínea/terapia , Factores de Coagulación Sanguínea/análisis , Transfusión Sanguínea , Humanos , Complicaciones Intraoperatorias , Cirrosis Hepática Alcohólica/complicaciones , Masculino , Persona de Mediana Edad , RiesgoRESUMEN
Using a standardized anaesthetic protocol, the continuous monitoring of the twitch height after a 0.1 Hz stimulus was used to follow the evolution of curarization following injection of either atracurium (0.6 mg . kg-1) or alcuronium (0.2 mg . kg-1). The maximum twitch height inhibition was always greater than 99% of the control value and occurred after 107 +/- 50 s with atracurium (n = 30) and 172 +/- 120 s for alcuronium (n = 30) (p less than 0.02). Although surgical stage of muscular relaxation (twitch height less than 25% of reference value) was the same for both drugs (55 +/- 15 min for alcuronium versus 52 +/- 10 min for atracurium; n = 30 for both groups), the clinical duration (spontaneous restoration of twitch height to 90% of the reference value) was significantly longer (p less than 0.005) for alcuronium: 89 +/- 20 min (n = 10) versus 62 +/- 9 min for atracurium (n = 10). The spontaneous return to normal of the train of four was also significantly longer (p less than 0.001) for alcuronium: 118 +/- 23 min (n = 10) versus 69 +/- 7 min for atracurium (n = 10). The recovery index (the time required for twitch height to rise from 25% to 75%) was three times quicker (p less than 0.01) for atracurium (10 +/- 3 min; n = 10) than for alcuronium (30 +/- 13 min; n = 10).(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Alcuronio/farmacología , Isoquinolinas/farmacología , Unión Neuromuscular/efectos de los fármacos , Fármacos Neuromusculares no Despolarizantes/farmacología , Toxiferina/análogos & derivados , Adolescente , Adulto , Alcuronio/administración & dosificación , Alcuronio/metabolismo , Anestesia General/métodos , Atracurio , Femenino , Humanos , Isoquinolinas/administración & dosificación , Isoquinolinas/metabolismo , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico , Contracción Muscular/efectos de los fármacos , Neostigmina/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/metabolismoRESUMEN
Prognosis value of initial clinical symptoms and findings in gas gangrene was evaluated in 72 patients. Fifty eight parameters were recorded. The relationship between the simultaneous effects of several variables upon survival was accomplished using the multivariate technique, discriminant analysis. On the basis of observed patients deaths or survivals, the individual condition weights were statistically derived in a manner that best distinguishes likely survivors from nonsurvivors. Six variables out of the 58 studied gave right classification of outcomes in 97 p. 100 of the patients.